AGMB · Nasdaq · CIK 0002020932

AgomAb Therapeutics NV

AgomAb Therapeutics NV’s most recent SEC filing in our snapshot is a Form 4 filed on Oct 22, 2026. Its EDGAR record lists 7 Form 4 insider filings from the 12 months before our last refresh.

SEC EDGAR snapshot updated Oct 27, 2026, 11:27 PM EDT. See all filings on sec.gov.

Revenue
—
Net income
—
Form 4 filings on record, past 12 months
7

Company overview

Legal name (as filed)
AgomAb Therapeutics NV
Ticker
AGMB
SEC Central Index Key (CIK)
0002020932
Business address
ANTWERPEN
State or country of incorporation
Belgium
Fiscal year ends
December 31
SEC filer category
Non-accelerated filer<br>Emerging growth company
Position in SEC ticker list
#2979 of the 3,000 companies we track

Five-year financial highlights

We could not find standardized annual figures for AgomAb Therapeutics NV in the SEC’s XBRL company facts. Read the latest annual report directly on EDGAR.

How to read these numbers

Revenue is the money a company brings in from selling its products and services; net income is what is left after all expenses, interest and taxes. Diluted EPS spreads net income across every share that could exist if options and convertible securities were exercised. Total assets and cash are balance-sheet figures measured on the last day of the fiscal year. For the full story — segment results, one-time charges, guidance — read Management’s Discussion and Analysis in the Form 10-K.

Latest key reports

The most recent filing of each major report type, even if it falls outside the 40 newest filings below.

AGMB latest annual, quarterly, current and proxy reports
FiledFormWhat it isOriginal
Apr 23, 202620-FAnnual report of a foreign private issuer· period Dec 31, 2025Document · Index
Oct 13, 20266-KReport of a foreign private issuer· period Oct 13, 2026Document · Index

Recent SEC filings

The 40 newest documents filed by or about AgomAb Therapeutics NV, by form type:

3 ×136-K ×114 ×7SCHEDULE 13G ×520-F ×1S-8 ×1SCHEDULE 13D ×1424B4 ×1
AGMB recent filings
FiledFormWhat it isOriginal
Oct 22, 20264Statement of changes in beneficial ownership (insider trade)· period Oct 21, 2026Document · Index
Oct 13, 20266-KReport of a foreign private issuer· period Oct 13, 2026Document · Index
Oct 9, 20264Statement of changes in beneficial ownership (insider trade)· period Oct 8, 2026Document · Index
Oct 7, 20264Statement of changes in beneficial ownership (insider trade)· period Oct 5, 2026Document · Index
Oct 7, 20264Statement of changes in beneficial ownership (insider trade)· period Oct 6, 2026Document · Index
Oct 7, 20264Statement of changes in beneficial ownership (insider trade)· period Oct 5, 2026Document · Index
Oct 1, 20266-KReport of a foreign private issuer· period Oct 1, 2026Document · Index
Sep 15, 20264Statement of changes in beneficial ownership (insider trade)· period Sep 11, 2026Document · Index
Sep 15, 20264Statement of changes in beneficial ownership (insider trade)· period Sep 11, 2026Document · Index
Sep 15, 20263Initial statement of beneficial ownership· period Sep 11, 2026Document · Index
Sep 15, 20263Initial statement of beneficial ownership· period Sep 11, 2026Document · Index
Sep 14, 20266-KReport of a foreign private issuer· period Sep 14, 2026Document · Index
Sep 11, 20266-KReport of a foreign private issuer· period Sep 11, 2026Document · Index
Aug 10, 20266-KReport of a foreign private issuer· period Aug 10, 2026Document · Index
Aug 6, 20266-KReport of a foreign private issuer· period Aug 6, 2026Document · Index
Jun 23, 20266-KReport of a foreign private issuer· period Jun 23, 2026Document · Index
May 27, 20266-KReport of a foreign private issuer· period May 27, 2026Document · Index
May 15, 2026SCHEDULE 13GPassive beneficial ownership report (over 5%)Document · Index
May 15, 2026SCHEDULE 13GPassive beneficial ownership report (over 5%)Document · Index
May 6, 2026SCHEDULE 13GPassive beneficial ownership report (over 5%)Document · Index
Apr 24, 20266-KReport of a foreign private issuer· period Apr 24, 2026Document · Index
Apr 23, 202620-FAnnual report of a foreign private issuer· period Dec 31, 2025Document · Index
Apr 16, 2026SCHEDULE 13GPassive beneficial ownership report (over 5%)Document · Index
Mar 18, 20263Initial statement of beneficial ownership· period Mar 18, 2026Document · Index
Mar 18, 20263Initial statement of beneficial ownership· period Mar 18, 2026Document · Index
Mar 18, 20263Initial statement of beneficial ownership· period Mar 18, 2026Document · Index
Mar 18, 20263Initial statement of beneficial ownership· period Mar 18, 2026Document · Index
Mar 18, 20263Initial statement of beneficial ownership· period Mar 18, 2026Document · Index
Mar 18, 20263Initial statement of beneficial ownership· period Mar 18, 2026Document · Index
Mar 18, 20263Initial statement of beneficial ownership· period Mar 18, 2026Document · Index
Mar 18, 20263Initial statement of beneficial ownership· period Mar 18, 2026Document · Index
Mar 18, 20263Initial statement of beneficial ownership· period Mar 18, 2026Document · Index
Mar 18, 20263Initial statement of beneficial ownership· period Mar 18, 2026Document · Index
Mar 18, 20263Initial statement of beneficial ownership· period Mar 18, 2026Document · Index
Mar 11, 2026S-8Registration of employee benefit plan securitiesDocument · Index
Mar 6, 2026SCHEDULE 13GPassive beneficial ownership report (over 5%)Document · Index
Mar 5, 20266-KReport of a foreign private issuer· period Mar 5, 2026Document · Index
Feb 17, 2026SCHEDULE 13DActive beneficial ownership report (over 5%)Document · Index
Feb 9, 20266-KReport of a foreign private issuer· period Feb 9, 2026Document · Index
Feb 6, 2026424B4424B4Document · Index

Insider filing activity

7 Form 4 filings appear in AgomAb Therapeutics NV’s EDGAR record between Oct 28, 2025 and our last refresh. Most are reports by the company’s own directors, officers and 10% owners, but EDGAR also lists a Form 4 under a company when the company itself is the insider — for example, when it owns more than 10% of another public company. Foreign private issuers’ own insiders generally do not file Form 4. A high count is not by itself a signal: many Form 4s report routine stock awards, tax withholding or sales under pre-arranged Rule 10b5-1 plans. Open each filing to see the transaction code, share count and price. What a Form 4 shows.

Other companies in Biological Products, (No Diagnostic Substances)

All 61 companies in Biological Products, (No Diagnostic Substances)

On Amazon

Popular tools for investors

As an Amazon Associate I earn from qualifying purchases.

Electronics Plaud Note Pro AI Voice Recorder An AI voice recorder that turns earnings calls and meetings into notes. View on Amazon → Electronics Amazon Kindle Paperwhite Signature Edition 32GB Read investing classics and long reports without eye strain. View on Amazon → Electronics Apple 2026 MacBook Air 13-inch Laptop A lightweight laptop for spreadsheets and filing research. View on Amazon →

Source

  • U.S. Securities and Exchange Commission, EDGAR submissions for CIK 0002020932 and XBRL company facts. AgomAb Therapeutics NV on EDGAR.
  • Snapshot updated Oct 27, 2026, 11:27 PM EDT. The SEC does not endorse OpenFilings. Company names and tickers are used only to identify the filer; no logos are shown.

Not investment advice. This page summarizes public SEC filings for information only. Figures may contain errors or omissions; confirm everything in the original filing before relying on it.